Gentel Biosciences

Gentel Launches CSA: Simian Expanded Product to Support Expanded SPF Colony Surveillance

06 December, 2011 Madison, WI

Gentel Biosciences, a provider of animal health research products, announces the launch of the Colony Surveillance Assays (CSA) for Expanded SPF nonhuman primate colony management.

Gentel officially launched the CSA: Simian Expanded panel on October 14, 2011 after extensive testing at several National Primate Centers

Gentel Launches CSA: Simian Expanded Product to Support Expanded SPF Colony Surveillance

“We enjoyed working with Gentel on a beta site trial of their CSA: Simian Expanded panel.  It gave accurate results and was easy to use," comments JoAnn Yee from the Pathogen Detection Laboratory at the California National Primate Research Center.

The CSA: Simian products provide the foundation for Gentel's growing animal health research product line that enables exceptional diagnostic accuracy for serological screening of non-human primates (NHP).

More information at www.CSA-Simian.com

According to Dan Clutter, Gentel's Vice President of Commercial Development, "Gentel’s mission is to improve colony monitoring by producing robust, high quality assays that are better than what people are currently using – for a fraction of the cost.  Our multiplex platform allows researchers to do more frequent and broader screening while still saving money and time.  Our CSA: Simian Expanded panel enables non-human primate colony surveillance for a broad selection of viral pathogens, including those important to the fields of comparative and translational medicine."

NHP models for disease are a critical component of translational research for disease models like HIV, an important model system for the human immune system and are often used in vaccine studies. Maintaining SPF status for these types of animal models is crucial to sustain the integrity of the study, ensure animal health, and prevent confounding results due to latent or opportunistic infections.

The CSA: Simian Expanded panel includes the gamma herpesviruses lymphocyptovirus (LCV) and rhesus rhadinovirus (RRV), the beta herpesvirus rhesus cytomegalovirus, (CMV) and the spumavirus simian foamy virus (SFV). These viruses have become of interest to researchers studying the immune system in primate models of human disease, because these common viral infections can recrudesce during studies where the immune system is compromised. To date, this is the first commercially available serological test for LCV, providing an alternative to more expensive and laborious PCR-based methods.

Gentel launched its product line supporting laboratory animal health in 2010 for non-human primates with its CSA: Simian Basic panel which includes 6 infectious agents monitored in SPF primates. The CSA: Simian Expanded panel includes an additional 5 infectious agents, for a total of 11 tests in one assay that takes under four hours. The CSA products use the Gentel Proteomics Multi-System™, a complete analysis platform that integrates data capture and analysis at a price that is comparable to that of a bench-top ELISA system.

About Gentel Biosciences, Inc.
Gentel delivers cost-effective, easy-to-use and reliable products to support laboratory animal health. These research products are designed to work with the Gentel Proteomics Multi-System™ (GPM), an all-in-one instrument for data capture and analysis. Gentel also has a strong portfolio of research oriented products for cancer biomarkers, cytokines, and tumor protein analysis, which also work with the GPM. Gentel's headquarters is located in Madison, Wisconsin.

Contact Information

For More Information:
Dan Clutter, Ph.D.
Vice-President, Commercial Development
Gentel Biosciences, Inc.
Phone: 608-441-2904

Meet the Gentel Team at a Scientific Conference Near You

Gentel Biosciences, a provider in animal health research products, will be highlighting its expanding Colony Surveillance Assay (CSA) products and the SilverQuant detection technology.

We would love to meet you at the following 2011 Conferences:

Gentel Announces Agreement With Oregon Health & Science University

Gentel Biosciences, a provider of animal health research products, announces today an agreement with Oregon Health & Science University (OHSU) to license viral antigens for use in Gentel's Colony Surveillance Assays (CSA).

Gentel licensed the viral antigens from OHSU for worldwide commercial use. These antigens were developed at the molecular virology core at OHSU's Oregon National Primate Research Center in Beaverton, Ore. The agreement was completed on August 9, 2011.

Gentel Announces Agreement to License B Virus Antigen from National B Virus Resource Center

Gentel Biosciences, a provider of animal health research products, announces today an agreement with the National B Virus Resource Center at Georgia State University for its B virus antigen to be licensed for use in Gentel’s Colony Surveillance Assays (CSA).

Gentel licensed the inactivated B virus antigen from the National B Virus Resource Center, at Georgia State University in Atlanta, GA for worldwide commercial use. The agreement was completed on July 22, 2011.

Gentel’s Native Protein Fractionation Array Technology Featured in Recent Publication

Gentel Biosciences, a leader in proteomics profiling tools, and Eprogen, jointly announce the publication of a new book chapter featuring Gentel's native fractionation array technology. The article can be found in the latest edition of the Springer Protocols' Methods and Protocols Series: Methods in Molecular Biology: Protein Microarray for Disease Analysis Methods and Protocols by Humana Press. The chapter entitled, "Native Antigen Fractionation Protein Microarrays for Biomarker Discovery", presents a detailed description of the creation and use of native protein fractionation arrays for autoantibody profiling.

Gentel Acquires SilverQuant Trademark from Eppendorf

Gentel Biosciences, a leader in proteomics profiling tools, announces today the introduction and use of the SilverQuant trademark for its protein array technology platform.

Gentel acquired the SilverQuant trademark from Eppendorf AG, Hamburg Germany for worldwide commercial use. The acquisition was completed on March 31, 2011.

Gentel Biosciences and Van Andel Institute Announce New Technology to Improve Early Detection and Prognosis of Cancer

Gentel Biosciences, a leader in proteomics tools, and Van Andel Research Institute (VARI), a biomedical research institute, jointly announce today the granting of U.S. Patent 7,838,634 for a new method to profile changes in the glycosylation of proteins captured on the surface of an antibody array slide. Gentel first obtained an exclusive right to commercialize the technology in 2006.

Gentel to showcase new Pathogen and Cytokine arrays at American College of Veterinary Pathologists Annual Meeting

Gentel Biosciences, a leader in proteomics profiling tools, will be highlighting its new SilverQuant® Simian Pathogen Array as well as over 30 animal-specific SilverQuant® Cytokine Kits at the American College of Veterinary Pathologists Annual Meeting in Baltimore.

Gentel Launches CSA: Simian Pathogen Arrays to Support Laboratory Animal Health Monitoring

Gentel Biosciences, a leader in proteomics profiling tools, announces the availability of the first Colony Surveillance Assay (CSA), robust viral antigen arrays and chromogenic-based detection kits, suitable for screening for specific antibodies to pathogens in the sera of non-human primates (NHP).

Gentel and RayBiotech Partner to Offer Comprehensive Selection of Arrays on SilverQuant® Chromogenic Detection Platform

Gentel Biosciences, a leader in proteomics profiling tools and RayBiotech, Inc., a pioneer and leader in protein and antibody array technologies, jointly announce today their partnership to develop and market RayBiotech’s vast collection of antibody array products covering a wide variety of cytokines and other proteins for use with Gentel's SilverQuant® chromogenic detection platform.